Explore
Validate
Learn
ELISA
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB4431-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Mouse VEGFR2/KDR/Flk-1 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects mouse VEGFR2 in Western blots.
- Reactivity
- Mouse
- Host
- Rat
- Conjugate
- Unconjugated
- Antigen sequence
P35918- Isotype
- IgG
- Antibody clone number
- 91202
- Vial size
- 100 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Mycobacterium tuberculosis exploits the formation of new blood vessels for its dissemination.
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.
alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner.
Polena H, Boudou F, Tilleul S, Dubois-Colas N, Lecointe C, Rakotosamimanana N, Pelizzola M, Andriamandimby SF, Raharimanga V, Charles P, Herrmann JL, Ricciardi-Castagnoli P, Rasolofo V, Gicquel B, Tailleux L
Scientific reports 2016 Sep 12;6:33162
Scientific reports 2016 Sep 12;6:33162
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M
The Journal of experimental medicine 2015 Feb 9;212(2):139-48
The Journal of experimental medicine 2015 Feb 9;212(2):139-48
Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.
Nagai N, Lundh von Leithner P, Izumi-Nagai K, Hosking B, Chang B, Hurd R, Adamson P, Adamis AP, Foxton RH, Ng YS, Shima DT
Investigative ophthalmology & visual science 2014 May 20;55(6):3709-19
Investigative ophthalmology & visual science 2014 May 20;55(6):3709-19
alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner.
Zhang Z, Ramirez NE, Yankeelov TE, Li Z, Ford LE, Qi Y, Pozzi A, Zutter MM
Blood 2008 Feb 15;111(4):1980-8
Blood 2008 Feb 15;111(4):1980-8
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- VEGFR2/KDR/Flk-1 Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Mouse VEGFR2/KDR/Flk-1 Antibody. Recombinant Mouse VEGFR2/KDR/Flk-1 Fc Chimera (Catalog # 443-KD) inhibits Recombinant Mouse VEGF164 (Catalog # 493-MV) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse VEGF164 (5 ng/mL) activity elicited by Recombinant Mouse VEGFR2/KDR/Flk-1 Fc Chimera (150 ng/mL) is neutralized (green line) by increasing concentrations of Mouse VEGFR2/KDR/Flk-1 Monoclonal Antibody (Catalog # MAB4431). The ND50 is typically 0.05-0.15 µg/mL.
